SCHEMBL20639239

SCHEMBL20639239

NC(=O)c1cccc(NC(=O)c2cc(Cl)c(Cl)cc2F)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 5/20 0.50
▸ PARP10 Q53GL7 5/20 0.50
▸ PARP15 Q460N3 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ KCNK3 O14649 1/20 0.50
▸ KCNK9 Q9NPC2 1/20 0.50
▸ PDE4A P27815 1/20 0.48
▸ PDE7A Q13946 1/20 0.48
▸ PPARG P37231 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ FADS1 O60427 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ PARP14 Q460N5 3/20 0.47
▸ GPR27 Q9NS67 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652637 0.88 HPGD (0.61) MEN1KMT2ASMN1; SMN2KCNK3KCNK9
SCHEMBL27654215 0.82 MEN1 (0.74) PARP1PARP10PARP15MEN1KMT2A
SCHEMBL20644107 0.80 SCN8A (0.62) —
SCHEMBL16398233 0.79 CA1 (0.63) MEN1KMT2A
SCHEMBL20639110 0.78 MAPT (0.56) MEN1KMT2ASMN1; SMN2KCNK3KCNK9
SCHEMBL20638776 0.78 MAPT (0.56) MEN1KMT2ASMN1; SMN2KCNK3PPARG
SCHEMBL20644052 0.78 SCN8A (0.66) SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL30530136 0.78 SCN8A (0.66) SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL20644073 0.78 SCN8A (0.56) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL31297250 0.78 SCN8A (0.56) MEN1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 — — US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 — — EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 — — US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 — — US disclosed
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2021-04-01 — — US disclosed
EP-3651752-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2020-05-20 — — EP disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 — — US disclosed
US-10647661-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-05-12 — — US disclosed
CN-111065383-A Carboxamides useful as sodium channel modulators 沃泰克斯药物股份有限公司 2020-04-24 — — CN disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 — — WO disclosed
WO-2019014352-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-01-17 — — WO disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 — — US disclosed
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885
US-20210094906-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885
US-10647661-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885
US-20190016671-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A PARP1 3762/4885PARP10 1201/4885PARP15 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback